Navigation Links
Signal Genetics and Pronto Diagnostics Announce Distribution Agreement

NEW YORK and TEL AVIV, Israel, April 4, 2011 /PRNewswire/ -- Signal Genetics, the parent company of Myeloma Health LLC, and Pronto Diagnostics Ltd, both of which are privately held predictive genetic testing companies focused on oncology, announced that they have entered into a Distribution Agreement whereby Pronto will be the exclusive representative and distributor for Signal's Myeloma Prognostic Risk Signature (MyPRS) test in Israel.  

According to Joe Hernandez, CEO of Signal Genetics, "The Agreement with Pronto Diagnostics represents our initial entry into the international market with MyPRS and strong interest among both laboratories and physicians outside the United States in providing broader access to this novel technology." Signal's MyPRS test is performed at the company's CLIA lab located in Little Rock, Arkansas and has been adopted by several highly reputable academic cancer centers throughout the U.S.

Dr. Nir Navot, Chairman and CTO of Pronto Diagnostics affirmed: "Our agreement with Signal Genetics allows us to provide a valuable prognostic tool to Israeli hematologists who treat Myeloma patients, in line with our commitment to increasing personalization of treatment for cancer patients".

About Signal Genetics

Signal Genetics, the parent company of Myeloma Health, is a privately held predictive genetic testing company focused on helping cancer patients. The goal of Signal Genetics is to provide cancer patients and their physicians with novel and innovative insights into their disease, including predictive outcome of disease stage, odds of relapse, and the optimal treatment regimen based on their specific genetic expression profile. Additional information is available at

About Pronto Diagnostics

Pronto Diagnostics is a privately held company based in Tel Aviv that provides services for molecular diagnosis of disease with a focus on oncology, including the development and distribution of genetic testing kits.  Pronto has similar distribution relationships with several molecular diagnostic companies including Ipsogen, Pathwork Diagnostics, and Epigenomics. Additional information is available at

SOURCE Signal Genetics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Signal Genetics and Caris Life Sciences Announce Commercialization Partnership for New Myeloma Gene Expression Test
2. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
3. Signal Genetics Announces Establishment of Scientific Advisory Board
4. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
5. TRINAMIC Teams with Actel's SmartFusion™ Intelligent Mixed Signal FPGAs for Motion Control
6. Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine
7. Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway
8. Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development
9. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
10. Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection
11. Revealing the regulating mechanism behind signal transduction in the brain
Post Your Comments:
(Date:10/13/2015)... ALBANY, New York , October 13, 2015 ... Share, Growth, Trends, and Forecast 2015 - 2023 " ... bn in 2014 and is anticipated to reach US$7.59 bn by ... from 2015 to 2023. --> " Microbiology Culture ... 2015 - 2023 " , the global microbiology ...
(Date:10/13/2015)... TapImmune, Inc. (TPIV), a ... peptide and gene-based immunotherapeutics and vaccines for the treatment ... presenting company at the Dawson James Small Cap ... Jupiter, Florida on October 15, ... clinical-stage immunotherapy company specializing in the development of innovative ...
(Date:10/13/2015)... Charlotte, NC (PRWEB) , ... October 13, 2015 ... ... high intensity focused ultrasound (HIFU) technologies, announced today that it received de novo ... 450 in the U.S. for the ablation of prostate tissue. Sonablate® is ...
(Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... Spirax Sarco, ... the release of the CSM-C 600 compact clean steam generator . This ... that meets the requirements of HTM2031, HTM2010, and EN285 standards. The CMS-C 600 ...
Breaking Biology Technology:
(Date:10/12/2015)... Research and Markets ( ) has announced the ... Market Shares, Strategies, and Forecasts, Worldwide, 2015-2021" to ... --> The study is designed to give a ... a selection from the mountains of data available of ... made by the most senior analysts. Commentary on every ...
(Date:10/12/2015)... , October 12, 2015 NXTD ) ... the growing mobile commerce market, reports on the recent SNS ... . --> NXTD ) ("NXT-ID" or the ... commerce market, reports on the recent SNS Future in Review ... --> NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ...
(Date:10/9/2015)... 2015 ... "Samsung Galaxy S6 Fingerprint Sensor - ... offering. --> ) has ... Galaxy S6 Fingerprint Sensor - Reverse Costing ... --> Research and Markets ( ...
Breaking Biology News(10 mins):